Rose became acquainted with Patient Worthy after her husband was diagnosed with Acute Myeloid Leukemia (AML) six years ago. During this period of partial remission, Rose researched investigational drugs to be prepared in the event of a relapse. Her husband died February 12, 2021 with a rare and unexplained occurrence of liver cancer possibly unrelated to AML.
Massimo Federico, MD, director of the medical oncology unit at the University of Modena and Reggio Emilia, Italy, was quoted in Cancer Network as saying that “Achieving a complete clinical and…
Continue Reading
Study Shows Impressive Results Using 3 Drug Combo in High-Risk Follicular Lymphoma
The Daily News recently published an announcement by researchers at Sangamo Therapeutics showing the results of its first human trial to treat two rare genetic disorders through gene-editing technology. Gene-editing (or…
Continue Reading
Researchers Fail to Find a Cure for MPS Through Genome Editing
A recent article in CheckOrphan describes a study that was conducted by Researchers at the Lysosomal and Rare Disorders Research and Treatment Center in Vancouver, B.C. The study examines the…
Continue Reading
Vancouver Researchers Find That Blood Cells Could Help Screen Ambroxol’s Efficacy in GD Type 3
Alexion Pharmaceuticals, Inc., a company that is advancing a rare disease pipeline in complement biology, recently issued a series of press releases announcing positive results of a Phase 3 study…
Continue Reading
Alexion’s Ultomiris™ Met the Primary Objective in a Phase 3 Trial of Atypical Hemolytic Uremic Syndrome Patients
Ofatumumab as a Single Agent Results of ofatumumab administered as a single agent with an extended induction (initial treatment) brought about a high response rate and it was well tolerated among follicular…
Continue Reading
Researchers Find the Future of Ofatumumab in Treating Follicular Lymphoma is Questionable
The treatment of metastatic renal cell carcinoma (RCC) has evolved over the last ten years and investigators now look towards combination therapies to improve response rates and durability for…
Continue Reading
Merck’s Keytruda in Combination with Pfizer’s Inlyta Significantly Improved Overall Survival and Progression-Free Survival in Therapy for Metastatic or Advanced Renal Cell Carcinoma
The Food and Drug Administration (FDA) recently announced its approval of Venetoclax (Venclexta) in combination with either decitabine or azacitidine (hypomethylating agents) or cytarabine (an antimetabolite) to treat adults 75 years…
Continue Reading
FDA Approves Venetoclax Combination For Newly Diagnosed AML in Adults 75 Years or Older
Source: pixabay
“Doctor” Onelio Hipolit-Gonzalez has been charged with unlicensed practice of a health care profession and unlawful use of a two-way communication device according to an article published in the Spectrum News of…
Continue Reading
73-Year-Old Arrested by Undercover Agents for Posing as a Physician
A report published in 2018 in The Hemotologist mentions the fact that most of the therapies introduced over the years for acute myeloid leukemia (AML) simply meant optimizing the use of…
Continue Reading
FDA Approves Four Novel Therapies for Acute Myeloid Leukemia
The University of Louisville’s publication UL News recently reported a finding by its research team regarding an immune checkpoint molecule. The molecule had been developed for cancer immunotherapy but when…
Continue Reading
University of Louisville’s Research Team Discovers Molecule That Protects Against Development of Cancer Cells
A recent interview with David Alvarez and his mother in the CTPost explains how he manages to remain positive after being diagnosed with spinal muscular atrophy (SMA). David is a freshman…
Continue Reading
College Freshman With Spinal Muscular Atrophy has Exciting Plans for the Future
In a recent article appearing in BioPortfolio, Orphan Technologies announced a Phase 1/2 clinical trial involving the first Classical Homocystinuria (HCU) patients to be treated with OT-58. Twelve patients were enrolled as…
Continue Reading
A Clinical Trial Now Testing a Novel, Engineered Enzyme for Patients with Classical Homocystinuria
A recent article in CheckOrphan reported that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the synthetic GLP-2 analog apraglutide for the treatment of short bowel syndrome…
Continue Reading
Orphan Drug Designation Granted to Therachon’s Drug Apraglutide by FDA for Treatment of Short Bowel Syndrome
ANCA Vasculitis News recently reported findings published in the journal Arthritis and Reumatology on the study “Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in ANCA‐Associated Vasculitis: A…
Continue Reading
Belimumab Maintenance Did Not Delay Relapse in AAV Patients
In a story published in The Hernando Sun, Dawn Dybiec, age 31, describes her disbelief when she and her husband were told that her two sons, Gabriel and Steven, were…
Continue Reading
One Family’s Struggle with Danon Disease, a Rare Disorder Affecting a Mother and Both of Her Two Young Sons
The Florey Institute of Neuroscience (FIN), one of the world’s largest and most respected brain research centers, recently announced trial results for the drug CuATSM, developed by FIN, the School…
Continue Reading
New Drug Improves Symptoms of Amyotrophic Lateral Sclerosis
Source: Pixabay
David Radford, a 63-year-old resident of Oxford, UK, and a liver cancer survivor, said his surgeon attributes his successful liver transplant to the new normothermic perfusion machine. As reported recently…
Continue Reading
New Storage Procedure May Increase the Number of Livers Used for Transplantation
source: pixabay.com
Pharnext SA, a biopharmaceutical company, recently announced results in a PLOS ONE article entitled "Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A…
Continue Reading
Pharnext Announces Preclinical Trial Results Affecting Onset of Charcot-Marie-Tooth Disease 1A
UPI Health News recently reported that a study, published in the New England Journal of Medicine, showed that fecal microbiota transplantation resulted in a 32 percent remission rate in patients…
Continue Reading
Fecal Microbiota Transplantation Achieved a 32 percent Remission in Ulcerative Colitis
Patients with acquired thrombotic thrombocytopenic purpura (aTTP) showed a significantly improved platelet count response after treatment with Cablivi® according to the New England Journal of Medicine's Phase 3 trial results. A…
Continue Reading
Positive Results for aTTP Announced by New England Journal of Medicine
A January 4th post by the Lancet's EBioMedicine headlined the first-in-human pilot study results published by UT Health San Antonio in collaboration with the Mayo Clinic and the Wake Forest School…
Continue Reading
Research in Humans Promote Findings for Deadly Age-Related Disease Treatment
Stephanie Hosford was recently interviewed by CURE (Cancer Updates Research and Education) about what she now calls her “three crazy days”. The title of her book is “Bald, Fat and…
Continue Reading
Looking Back With Humor: She Survived and Wrote a Book About How She Fought For Her Children, Her Life, and Her Sanity